CDK3

Across TCGA pan-cancer cohorts, CDK3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDK3 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CDK3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDK3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, LIHC, and SKCM are the cancer types where CDK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.074	0.667	<.001	30	view →
LIHC	DFS	Median	All	0.060	0.544	<.001	24	view →
SKCM	DFS	Median	II,III,IV	1.000	0.665	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CDK3–STAD (OS)

Open the STAD breakdown →